Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon-beta-CTP
- Development stage
- Preclinical
- Lead developer
- OPKO Health
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
Interferon-beta-CTP (also known as MOD-9023) is a long-acting recombinant fusion protein consisting of human interferon beta-1a modified with C-terminal peptide (CTP) sequences derived from the human chorionic gonadotropin (hCG) beta subunit. Developed by PROLOR Biotech (now part of OPKO Health), the CTP technology significantly extends the drug's half-life and systemic exposure compared to standard interferon beta products. It acts as an agonist at the type I interferon receptors (IFNAR1 and IFNAR2), modulating immune responses and reducing inflammation. The primary therapeutic goal is to treat multiple sclerosis (MS) with a reduced injection frequency, improving patient compliance. Preclinical studies have also demonstrated potential anti-tumor activity in melanoma models.
- Other names
- CTP-modified human interferon betaLong-acting interferon beta-1a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on interferon-beta-CTP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon-beta-CTP.